Cellect Biotechnology Ltd. (APOP) Stock: Seeing Declines In Today’s Session


Cellect Biotechnology Ltd. (APOP) is falling in the market in today’s trading session. The company, focused on the biotechnology space, is currently priced at $0.52 after a move down of -10.34% so far today. As it relates to biotechnology companies, there are several factors that have the potential to generate movement in the market. News is one of the most common reasons for movement. Here are the recent stories surrounding APOP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-13-19 12:28PM A Look At Benzinga Pro’s Most-Searched Tickers For August 13, 2019
08:00AM Cellect Biotechnology Reports Second Quarter 2019 Financial and Operating Results
Aug-12-19 11:35AM Cellect Shares Rally After Lead Stem Cell Program Receives Clearance For Midstage Study
07:00AM Cellect Biotechnology Announces Positive Outcome From Safety Review Committee; Successfully Transplants 9th Clinical Trial Patient
Jul-08-19 07:00AM Cellect Biotechnology and Washington University (WU) Finalize Accelerated Clinical Trial Agreement

However, when making a decision to invest, investors should look at much more than news, especially in the highly speculative biotechnology industry. Here’s what’s happening in regard to Cellect Biotechnology Ltd..

Returns That APOP Investors Have Seen

Although a decline in a single session, like the fall that we’re seeing from Cellect Biotechnology Ltd. may cause fear in some investors, a single session move alone should not be the basis of a decision to, or not to, buy a company’s stock. It is always smart to dig into trends experienced by the stock beyond a single trading session. In the case of APOP, below are the returns on investment that investors have seen:

  • Past 5 Sessions – Over the past 5 trading sessions, APOP has seen a change in value that amounts to -1.66%.
  • Past Month – The performance from Cellect Biotechnology Ltd. throughout the past month works out to 4.00%.
  • Past 3 Months – In the last 3 months, the stock has generated a return that works out to -30.61%
  • Past Six Months – Over the last six months, we’ve seen a change that equates to -51.85% from the stock.
  • YTD – Since the open of this year APOP has generated a ROI of -75.24%.
  • Annually – Lastly, over the last year, we’ve seen a change in the amount of -89.60% out of APOP. Throughout this period, the stock has sold at a high of -91.35% and a low of 29.19%.

Important Ratios

Digging into various key ratios associated with a company can give traders a look of how risky and/or potentially profitable a stock pick may be. Below are a few of the key ratios to look at when digging into APOP.

Short Ratio – The short ratio is a measure of short interest. As the ratio heads up, it shows that more investors believe that the value of the stock is going to fall. Throughout the sector, biotechnology stocks tend to have a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, with regard to Cellect Biotechnology Ltd., it’s short ratio is 0.04.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure If a company is able to pay its debts when they come due with only current assets or quick assets. In the biotech sector, companies rely heavily on the continuation of support from investors, the quick and current ratios can seem damning. Nonetheless, several gems in the biotech industry do have good current and quick ratios. As far as APOP, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price. In the case of Cellect Biotechnology Ltd., the book to share value ratio works out to 0.69.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to think about. In terms of APOP, the cash to share value is 0.

What Analysts Think About Cellect Biotechnology Ltd.

While it’s never a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their opinions to validate your own thoughts when it comes to making investment decisions in the biotech industry. Here are the most recent moves that we have seen from analysts with regard to APOP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-25-17 Reiterated H.C. Wainwright Buy $12 → $14

Is Big Money Interested in Cellect Biotechnology Ltd.?

One thing that I’ve come to understand in my short period on Earth is that smart investors tend to follow big money players. So, investors that are looking to play it relatively safe will keep an eye on trades made by institutional investors and those on the inside. So, where is the big money as it relates to APOP? Here’s the data:

  • Institutions – As it stands now, institutions hold 0 of Cellect Biotechnology Ltd.. However, it’s important to mention that the ownership held by institutions has changed in the amount of 0 over the last quarter.
  • Insiders – As far as insiders go, insiders of the company currently own 54.73% of the company. Insider ownership of the company has changed by 0.00% in the past quarter.

What’s Going On With Share Counts?

Investors and traders seem to have an interest in the total numbers of shares both available and outstanding. In terms of Cellect Biotechnology Ltd., currently there are 11.20M with a float of 8.78M. These data mean that out of the total of 11.20M shares of APOP in existence today, 8.78M are able to be traded in the public realm.

It’s also important to dig into the short percentage of the float. Think about it, when a large percentage of the float is shorted, the overall opinion among traders is that the stock is going to fall. When it comes to APOP, the percentage of the float that is sold short comes to a total of 0.11%. In general, high short percent of the float would be anything over 40%. Through my work, I’ve calculated that a short ratio over 26% is probably going to be a play that comes with hefty risk.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, APOP has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was developed by a human and human beings actually play an important role in my ability to learn. Sure, I can dig through social trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, leave a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here